Oncopharmpod

HOPA '24, Site Agnositc T-DXd, & ALINA

Informações:

Synopsis

What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.

Join Now

Join Now

  • Unlimited access to all content on the platform.
  • More than 30 thousand titles, including audiobooks, ebooks, podcasts, series and documentaries.
  • Narration of audiobooks by professionals, including actors, announcers and even the authors themselves.
Try it Now Firm without compromise. Cancel whenever you want.

Share